Health care resources and costs associated with delivering gene therapy for hemophilia in clinical practice
Delivery of hemophilia gene therapy requires significant resources, incurs substantial costs, and demands additional organizational infrastructure within treatment facilities. These findings may aid stakeholders to better plan implementation of these innovative therapies into clinical practice, as well as inform economic evaluations and reimbursement discussions.
Institutions
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- Utrecht University (NL)
- Erasmus MC (NL)
- Pulmonary Hypertension Association (US)
- University Medical Center Utrecht (NL)
- Erasmus MC - Sophia Children’s Hospital (NL)
- Amsterdam University of Applied Sciences (NL)
- University of Amsterdam (NL)
Publication Details
- Journal
- Research and Practice in Thrombosis and Haemostasis
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1016/j.rpth.2025.103275
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00